We are live on ! Find out more
BBH icon

VanEck Biotech ETF

105 hedge funds and large institutions have $136M invested in VanEck Biotech ETF in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

285% more call options, than puts

Call options by funds: $1.37M | Put options by funds: $355K

15% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 26

11% more capital invested

Capital invested by funds: $123M → $136M (+$13.4M)

2.41% more ownership

Funds ownership: 25.65%28.06% (+2.4%)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

3% less funds holding

Funds holding: 108105 (-3)

Holders
105
Holders Change
-3
Holders Change %
-2.78%
% of All Funds
1.84%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
30
Reduced
26
Closed
9
Calls
$1.37M
Puts
$355K
Net Calls
+$1.01M
Net Calls Change
+$1.25M

BBH Hedge Fund Activity: Q1 2021 in Review

105 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2021, worth a combined $136M — up 11% from $123M a quarter earlier.

Fund positioning in BBH was balanced in Q1 2021: 9 funds opened new positions, 9 closed out, 30 added to existing stakes and 26 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $9.04M. The largest seller was Royal Bank of Canada, cutting an estimated $1.8M.

  • 105 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2021, down from 108 in Q4 2020.
  • Funds reported $136M of VanEck Biotech ETF stock for Q1 2021, up 11% quarter-over-quarter.
  • 9 funds opened new VanEck Biotech ETF positions in Q1 2021 and 9 closed out, a net change of 0 holders.
  • The largest VanEck Biotech ETF buyer in Q1 2021 was Goldman Sachs, an estimated $9.04M added.
  • The largest VanEck Biotech ETF seller in Q1 2021 was Royal Bank of Canada, an estimated $1.8M sold.

Based on aggregated 13F filings for Q1 2021.